It is a sign that Novo Nordisk's efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to skyrocket in the U.S.

The diabetes and weight loss medications Ozempic and Wegovy are now considered to be available after more than two years after being declared in shortage by the Food and Drug Administration (FDA).

All doses of the two drugs are now listed as available in the U.S., per an FDA database, although the company cautioned patients may still experience "variability" filling their prescriptions.